INTRODUCTION

Asfotase alfa (brand name Strensiq) is an engineered glycoprotein that is used as an enzyme replacement therapy in the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP).

This plasmid is designed for expressing Asfotase alfa in mammalian expression system such as Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-25
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Asfotase alfa
Brand Names: Strensiq
Classification: Fusion proteins
Action Type: Enzyme replacement therapy
Amino Acid Sequence: Identical to DB09105

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, Thompson DD, Bishop N, Hofmann C. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. J Clin Endocrinol Metab. 2016 Jan;101(1):334-42.

Contact Us